Borealis appoints IMCD as Bormed™ healthcare portfolio distributor

Photo: The distribution agreement applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices. Ⓒ Borealis
The distribution agreement will take effect as of October 1, 2021. The new agreement applies to Bormed™ portfolio of innovative polyolefin grades for healthcare. Complementary Borealis and IMCD product portfolios will enable even more choice in polymers.
Borealis announces that it has selected IMCD, a global leader in the distribution of specialty chemicals and ingredients, as its new European distributor of its dedicated grade range of Bormed™ polyolefins for healthcare.
The distribution agreement covers most of Europe (with the exception of Switzerland and the South-Eastern countries) and takes effect as of 1 October 2021. It applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices.
As a distributor with a strong presence in medical and healthcare applications, IMCD is the ideal partner for Borealis customers in Europe thanks to its broad technical expertise and dedicated medical application team. The extensive IMCD polymers range complements the Borealis Bormed portfolio, opening a range of new possibilities.
IMCD was selected from a broad field of potential distributors following a rigorous screening process.
“We are pleased to have found in IMCD a partner sharing the core Bormed values of service, commitment and conformance,” said John Webster, Borealis Head of Sales Advanced Products.
“What also unites us is our dedication to providing best-in-class service to all of our healthcare customers, both direct and indirect, by way of more intensive and efficient value chain collaboration. We are confident that this new agreement will significantly boost our presence in this increasingly important sector.”
In line with its commitment to service as the foundation of successful industry co-operation, Borealis and IMCD will together ensure a seamless distribution transition for their customers, who can continue to count on security of supply as well as the ready assistance of experienced technical and sales teams.
Olivier Champault, Director of IMCD Business Group Advanced Materials said: “We are delighted to be selected as the new partner for Borealis in their healthcare business. This partnership is completely aligned with our strategy to further expand and strengthen our presence in the medical and healthcare segment in Europe.
With our dedicated experts in medical and healthcare applications, our well-established distribution network, and our board product offering, we are fully committed to accelerate growth and to support our customers in their developments and innovations.”

Related News
-
News Lonza and Touchlight collaboration to bring expanded end-to-end mRNA offerings
Through a collaboration with biotech company Touchlight, Lonza is set to expand their end-to-end offering for mRNA manufacturing with additional DNA raw material sources, including Touchlight’s doggybone DNA. -
News Oxford University presents promising phase II data for malaria vaccine
The malaria vaccine R21/Matrix-M, developed by researchers at Oxford University, has produced encouraging new data for the global effort against the mosquito-borne disease. -
News NextPharma to acquire Norway manufacturing site from Takeda
Biopharmaceutical company Takeda and CDMO NextPharma have announced an acquisition agreement in which Takeda will divest from their Asker, Norway manufacturing site, set to be acquired by NextPharma. -
News Novavax COVID-19 vaccine receives backing from European Medicines Agency
The European Medicines Agency has backed the Nuvaxovid COVID-19 vaccine for adults as a booster shot to other COVID-19 vaccines. -
News Moderna sues Pfizer/BioNTech over COVID-19 vaccine patent infringement
The pharmaceutical companies behind the leading COVID-19 vaccines are in a legal dispute over intellectual property rights surrounding the mRNA vaccines that were released after emergency use authorization in December 2020. -
News Accepting novel excipients for innovative drug development
With the rapid development and manufacturing of new drugs and therapeutics being pushed through the pipeline, excipient manufacturers are navigating a challenging landscape to meet the demand for new and novel excipients. -
News ChargePoint Technology acquires PuroVaso for greater range of powder and liquid transfer solutions
ChargePoint Technology has acquired PuroVaso, leader in the design, development, and manufacture of single-use containers, handling equipment, and accessories for pharma, biopharma, and life sciences. -
News Lonza adds X-ray powder diffraction to micronisation portfolio in Monteggio (CH)
Lonza expands solid-state characterisation services for polymorph and solid-state properties of APIs with the addition of X-ray powder diffraction to its portfolio.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance